首页> 外文OA文献 >Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.
【2h】

Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.

机译:粒细胞集落刺激因子加促红细胞生成素治疗骨髓增生异常综合症的贫血:一项来自II期随机研究的结果,并对71位患者进行了长期随访。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Treatment with erythropoietin (epo) may improve the anemia of myelodysplastic syndromes (MDS) in approximately 20% of patients. Previous studies have suggested that treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and epo may increase this response rate. In the present phase II study, patients with MDS and anemia were randomized to treatment with G-CSF + epo according to one of two alternatives; arm A starting with G-CSF for 4 weeks followed by the combination for 12 weeks, and arm B starting with epo for 8 weeks followed by the combination for 10 weeks. Fifty evaluable patients (10 refractory anemia [RA], 13 refractory anemia with ring sideroblasts [RARS], and 27 refractory anemia with excess blasts [RAEB]) were included in the study, three were evaluable only for epo as monotherapy and 47 for the combined treatment. The overall response rate to G-CSF + epo was 38%, which is identical to that in our previous study. The response rates for patients with RA, RARS, and RAEB were 20%, 46%, and 37%, respectively. Response rates were identical in the two treatment groups indicating that an initial treatment with G-CSF was not neccessary for a response to the combination. Nine patients in arm B showed a response to the combined treatment, but only three of these responded to epo alone. This suggests a synergistic effect in vivo by G-CSF + epo. A long-term follow-up was made on 71 evaluable patients from both the present and the preceding Scandinavian study on G-CSF + epo. Median survival was 26 months, and the overall risk of leukemic transformation during a median follow-up of 43 months was 28%. Twenty patients entered long-term maintenance treatment and showed a median duration of response of 24 months.The international prognostic scoring system (IPSS) was effective to predict survival, leukemic transformation, and to a lesser extent, duration of response, but had no impact on primary response rates.
机译:促红细胞生成素(epo)的治疗可能会改善大约20%的患者的骨髓增生异常综合症(MDS)的贫血。先前的研究表明,粒细胞集落刺激因子(G-CSF)和epo的联合治疗可能会提高这种反应率。在目前的II期研究中,根据两种选择之一,将MDS和贫血患者随机分配接受G-CSF + epo治疗。 A组从G-CSF开始持续4周,然后合并12周,B组从epo开始持续8周,然后合并10周。该研究纳入了50例可评估患者(10例难治性贫血[RA],13例伴环铁粒母细胞难治性贫血[RARS]和27例难治性贫血伴过度成胚细胞[RAEB]),其中3例仅作为单药治疗就可评估为epo,而47例对联合治疗。对G-CSF + epo的总缓解率为38%,与我们先前的研究相同。 RA,RARS和RAEB患者的缓解率分别为20%,46%和37%。在两个治疗组中,缓解率相同,这表明对于联合治疗而言,无需使用G-CSF进行初始治疗。 B组中有9名患者对联合治疗有反应,但其中只有3名患者对epo单独治疗。这表明G-CSF + epo在体内具有协同作用。对目前和先前斯堪的纳维亚关于G-CSF + epo的研究进行评估的71名可评估患者进行了长期随访。中位生存期为26个月,中位随访43个月期间发生白血病转化的总体风险为28%。 20名患者接受了长期维持治疗,平均反应时间为24个月。国际预后评分系统(IPSS)可有效预测生存率,白血病转化率,并在较小程度上预测反应时间,但没有影响主要反应率。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号